Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Corticosteroids and Cancer Immunotherapy
Rachel Goodman, Douglas B. Johnson, Justin M. Balko
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2580-2587
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Guihong Wan, Wenxin Chen, Sara Khattab, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1053-1069
Closed Access | Times Cited: 15
Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review
Roma Kankaria, Douglas B. Johnson
The Oncologist (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Engineered algae microrobots as photosynthetic living materials promote T cells’ anti-tumor immunity
Fanqiang Meng, Lin Zhong-da, Yumeng Ma, et al.
Cell Reports Physical Science (2024) Vol. 5, Iss. 6, pp. 102023-102023
Open Access | Times Cited: 11
O-carboxymethyl chitosan in biomedicine: A review
Lingbin Chen, Yandi Xie, Xiaohang Chen, et al.
International Journal of Biological Macromolecules (2024) Vol. 275, pp. 133465-133465
Closed Access | Times Cited: 11
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 6
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 13
Comparative study of management strategies for immune checkpoint inhibitor‐induced inflammatory arthritis: rheumatologists versus oncologists
Ji-Hyang Yoon, Frances Zhao, Hajira Masood, et al.
Internal Medicine Journal (2025)
Closed Access
High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial
Verena Theiler‐Schwetz, Georg Trummer, Lisa Schmitt, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
Immunotherapy and palliative medicine: opportunities and challenges
Nessa Keane, Lynda McSorley, Leona Reilly
BMJ Supportive & Palliative Care (2025), pp. spcare-005362
Closed Access
Common Drug-Drug and Drug-Food Interactions in Antineoplastic Agents: A short update review
Sonia Sanajou, Terken Baydar
Hacettepe University Journal of the Faculty of Pharmacy (2025) Vol. 45, Iss. 1, pp. 92-105
Closed Access
Rethinking corticosteroids use in oncology
Pierrick Martinez, Jean‐Marc Sabatier
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma
Takuto Hara, Kotaro Suzuki, Taisuke Tobe, et al.
International Urology and Nephrology (2025)
Closed Access
Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?
Alessandro Ottaiano, Mariachiara Santorsola, Maurizio Capuozzo, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H. Sodergren, Rose Hodgson, et al.
Cell Reports Medicine (2025), pp. 102041-102041
Open Access
Oral Budesonide in Oncology: A Novel Approach to Managing Gastrointestinal Immune-Related Adverse Events
Piotr Wysocki, Jarosław Reguła
Current Treatment Options in Oncology (2025)
Closed Access
LymphoDose: a lymphocyte dose estimation framework—application to brain radiotherapy
François de Kermenguy, Nathan Benzazon, Pauline Maury, et al.
Physics in Medicine and Biology (2024) Vol. 69, Iss. 10, pp. 105009-105009
Open Access | Times Cited: 4
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer
Luca Licata, Maria Vittoria Dieci, Carmine De Angelis, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102762-102762
Open Access | Times Cited: 4
Changing the Landscape of Solid Tumor Therapy from Apoptosis-Promoting to Apoptosis-Inhibiting Strategies
Razmik Mirzayans
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5379-5396
Open Access | Times Cited: 4
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events
Sara Khattab, Guihong Wan, Suzanne Xu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Risk factors associated with immune-related severe adverse events: A scoping review
Zhenzhen Su, Liyan Zhang, Xuemin Lian, et al.
Asia-Pacific Journal of Oncology Nursing (2025) Vol. 12, pp. 100661-100661
Open Access
Immune-mediated colitis after immune checkpoint inhibitor therapy
Sophie Giesler, R. Kirk Riemer, Theresa Lowinus, et al.
Trends in Molecular Medicine (2024)
Open Access | Times Cited: 3
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
Danilo Rocco, Luigi Della Gravara, Angela Ragone, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4684-4684
Open Access | Times Cited: 8
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
Elio Gregory Pizzutilo, Rebecca Romanò, Laura Roazzi, et al.
Cancer Research (2023) Vol. 83, Iss. 14, pp. 2283-2296
Open Access | Times Cited: 7
Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
Soh Mee Park, Yu Jung Kim, Ju‐Yeun Lee
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top